Table D2. Study characteristics, part 1

| Author, YearTrial Name | N Eligible | N Randomized | N Completers | N Analyzed | Study Design |
| --- | --- | --- | --- | --- | --- |
| Bender et al., 20101NA | NR | Overall N: 50G1: 25G2: 25 | NR | Overall N: 50G1: 25G2: 25 | RCT: parallel, not clustered |
| Berg et al., 19972NA | Overall N: 87G1: NRG2: NR | Overall N: 55G1: 31G2: 24 | Overall N: 54G1: NRG2: NR | Overall N: 55G1: 31G2: 24 | Non-clustered RTC with block randomization by asthma severity |
| Berger et al., 20053NA | Overall N: NRG1: G2:  | Overall N: 435 G1: 212G2: 212(the article does not account for the discrepancy in these numbers) | Overall N: 367G1: 172G2: 195 | Overall N: 367G1: 172G2: 195 | RCT: parallel, not clustered |
| Bogner et al., 20084NA | Overall N: 109 prescreened as potentially eligible - 73 provided consent for screeningG1: NRG2: NR | Overall N: 64G1: 32G2: 32  | Overall N: 64G1: 32G2: 32  | Overall N: 64G1: 32G2: 32  | RCT: parallel, not clustered |
| Bogner et al., 20105NA | Overall N: 58G1: 29G2: 29 | Overall N: 58G1: 29G2: 29 | Overall N: 58G1: 29G2: 29 | Overall N: 58G1: 29G2: 29 | RCT: parallel, not clustered |
| Bosworth et al., 20056V-STITCH | Overall N: 816G1: NRG2: NR | Overall N: 588G1: 294G2: 294 | Overall N: NRG1: NRG2: NR | Overall N: NRG1: NRG2: NR | RCT: parallel, not clustered |
| Bosworth et al., 20087TCYBBosworth et al., 20078TCYB Methods paper | Overall N: NR, unclear from textG1: NRG2: NR | Overall N: 636G1: 319G2: 317 | Overall N: NRG1: NRG2: NR | Overall N: NRG1: NRG2: NR | RCT: parallel, not clustered |
| Capoccia et al., 20049NA | Overall N: 89G1: G2:  | Overall N: 74G1: 41G2: 33 | Overall N: 69G1: 37G2: 30 | Overall N: 74G1: 41G2: 33 | RCT: parallel, not clustered |
| Carter et al., 200910NA | Overall N: 1242G1: 568G2: 674 | Overall N: 402G1: 192G2: 210 | Overall N: 332G1: 158G2: 174 | Overall N: 402G1: 192G2: 210 | RCT: cluster-randomized |
| Chernew et al., 200811NA | Number of members in health planOverall N (2004): G1: 35,807G2: 74,345Overall N (2005): G1: 37,867G2: 70,259 | NA | NR | For diabetes medications:2004 (Pre):G1: 919 to 1,245G2: 3,596 to 4,1852005 (Post):G1:1,056 to 1,306G2: 3,535 to 4,072Unit of observation in analyses was patient-quarter, yielding eight observations per patient | Before-after study |
| Choudhry et al., 201012NA | Overall N: 52,631G1: 2051G2: 779G3: 38,174G4: 11,627 | Overall N: NAG1: NAG2: NA | Overall N: 52,631G1: 2051G2: 779G3: 38,174G4: 11,627 | Overall N: 52,631G1: 2051G2: 779G3: 38,174G4: 11,627 | Other  |
| Choudhry et al., 201113MI FREEE | Overall N: 6768G1: G2: | Overall N: 5855G1: 2845G2: 3010 | Overall N: 5571G1: 2712G2: 2859 | Overall N: 5571G1: 2712G2: 2859 | RCT: cluster-randomized |
| Friedman et al., 199614NA | Overall N: 964G1: NRG2: NR | Overall N: 299G1: NRG2: NR | Overall N: 267G1: 133G2: 134 | Overall N: 267G1: 133G2: 134 | RCT: parallel, not clustered |
| Fulmer et al., 199915NA | Overall N: 600G1: G2:  | Overall N: 60G1: NRG2: NRG3: NR | Overall N: 50G1: 17G2: 15G3: 18 | Overall N: 50G1: 17G2: 15G3: 18 | RCT: parallel, not clustered |
| Grant et al., 200316NA | Overall N: 462G1: 118G2: 114 G3: 230 | Overall N: 462G1: 118G2: 114 G3: 230 | Overall N: 120G1: 62G2: 58 | Overall N: 120G1: 62G2: 58 | RCT: parallel, not clustered |
| Guthrie et al., 200117First Myocardial Infarction (MI) Risk Reduction Program | Overall N: NRG1: NRG2: NR | Overall N: 13,100G1: 10,335G2: 2,765 | Overall N: 4548G1: 3635G2: 913 | Overall N: 4548G1: 3635G2: 913 | RCT: parallel, not clustered |
| Hoffman et al., 200318NA | NR | Overall : Patients: 9564Providers: 7021G1: Patients: 4899 Providers: 3474G2: Patients: 4665Providers: 3547 | Overall N: G1: G2:  | Overall N: G1: G2:  | RCT: cluster-randomized |
| Hunt et al., 200819NA | Overall N: 2,901G1: NRG2: NR | Overall N: 463G1: 230G2: 233 | Overall N: 272G1: 142G2: 130 | Overall N: 272G1: 142G2: 130 | RCT: parallel, not clustered |
| Janson et al., 200320NA | Overall N: NRG1: NRG2: NR | Overall N: 68G1: NRG2: NR | Overall N: 62G1: NRG2: NR | Overall N: 65G1: 33G2: 32 | RCT: parallel, not clustered |
| Janson et al., 200921NA | Overall N: 95G1: NAG2: NA | Overall N: 84G1: 45G2: 39 | NR | Overall N: G1: 45G2: 39 | RCT: parallel, not clustered |
| Johnson et al., 200623NR | Overall N: 1227G1: NRG2: NR | Overall N: NRG1: NRG2: NR | Overall N: NRG1: NRG2: NR | Overall N: 1017G1: 500G2: 517 | RCT: parallel, not clustered |
| Johnson et al., 200622NR | Overall N: 1038G1: NRG2: NR | Overall N: 404G1: 202G2: 202 | Overall N: 262G1: 114G2: 148 | Overall N: 404G1: 202G2: 202 | RCT: parallel, not clustered |
| Katon et al., 199524NA | Overall N: 242G1: G2:  | Overall N: 217Major depression group N: 91G1: 49G2: 42Minor depression group N: 126G1: 59G2: 67 | Overall N: 177G1: NRG2: NR | Overall N: 177G1: NRG2: NR | RCT: cluster-randomized |
| Katon et al., 199625NA | Overall N: 183 | Overall N: 153G1: 77G2: 76Major depression: 65Minor depression: 88 | Overall N: 113G1: 60G2: 53 | N analyzed NR, but stated to include "all intervention patients" for adherence outcomes, unclear for other outcomes | RCT: cluster-randomized |
| Katon et al., 200128 NALudman et al., 200329NAVan Korff et al., 200330NA | Overall N: 480 | Overall N: 386G1: 194G2: 192 | Overall N: 315G1: 170G2: 145 | Overall N: 315G1: 170G2: 145 | RCT: parallel, not clustered |
| Katon et al., 199926NAKaton et al., 200227NA | Overall N: 341 | Overall N: 228G1: 114G2: 114 | 6 m:Overall N: 167G1: 87G2: 8028 m: Overall N: 171G1: NRG2: NR | 6 m:Overall N: 228G1: 114G2: 11428 m:Overall N: 187G1: 95G2: 92 | RCT: parallel, not clustered |
| Lee et al., 200631FAME | Overall N: 208G1: NRG2: NR | Overall N: 159G1: 83G2: 76 | Overall N: 146G1: 77G2: 69 | Overall N: 159G1: 83G2: 76 | RCT: parallel, not clustered |
| Lin et al., 200632NA | Overall N: 375G1: NAG2: NA | Overall N: 329G1: 164G2: 165 | Overall N: NR | Overall N: 329G1: 164G2: 165 | RCT: parallel, not clustered |
| Maciejewski et al., 20103315257NA | Overall N: NRG1: NRG2: NR | EnrolleesOverall N: 1385391G1: 747300G2: 638091All employersOverall N: 32259G1: 32083G2: 176Underwritten employersOverall N: 32032G1: 32032G2: 0Self-insured employersOverall N: 227G1: 51G2: 176 | Overall N: NRG1: NRG2: NR | Enrollees**Overall N**: 1385391G1: 747300G2: 638091**Diuretics**Overall N: NRG1: 15605G2: 9137**ACE Inhibitors**Overall N: NRG1: 14250G2: 7668**Statins**Overall N: NRG1: 18346G2: 10162**Beta Blockers**Overall N: NRG1: 11137G2: 6343**Calcium Channel Blockers**Overall N: NRG1: 7191G2: 4099**Metformin**Overall N: NRG1: 5077G2: 2826**ARBs** Overall N: NRG1: 7445G2: 4514**Cholesterol Absorption Inhibitors**Overall N: NRG1: 4019G2: 2291 | Retrospective quasi-experimental |
| Mann et al., 201034The Statin Choice | NR | Overall N: 150G1: 80 G2: 70 | NR | NR | RCT: parallel, not clustered |
| Montori et al., 201135NA | Overall N: 102G1: NAG2: NA | Overall N: 100G1: 52G2: 48 | Overall N: 93G1: 47G2: 46 | Overall N: 100G1: 52G2: 48 | RCT: parallel, not clustered |
| Murray et al., 200736NA | Overall N: 1512 G1: NRG2: NR | Overall N: 314G1: 122G2: 192 | Overall N: 270G1: 106G2: 164 | Overall N: 314G1: 122G2: 192 | Randomized clinical trial |
| Nietert et al., 200937NA | Overall N: 3048G1: NRG2: NRG3: NR | Overall N: 3048G1: 1018G2: 1016G3: 1014 | Overall N: 2590G1: 869G2: 863G3: 858 | Overall N: 3048G1: 1018G2: 1016G3: 1014 | RCT: parallel, not clustered |
| Okeke et al., 200938NA | Overall N: 66G1: G2:  | Overall N: 66G1: 35G2: 31 | Overall N: NRG1: NRG2: NR | Overall N: 66G1: 35G2: 31\*4 excluded from multivariate analysis (1 from G1 and 2 from G2) due to missing value in education (N=2), Asian race (N=1), and use of travoprost without using dosing aid (N=1) | RCT: parallel, not clustered |
| Pearce et al., 200839Cardiovascular Risk Education and Social Support (CaRESS) Trial | Overall N: 233G1: NRG2: NRG3: NR | Overall N: 199G1: 50G2: 58G3: 91 | Overall N: 153G1 + G2: 81G3: 72 | Overall N: 199G1: 50G2: 58G3: 91 | RCT: cluster-randomized |
| Powell et al., 199540NA | Overall N: NRG1: NRG2: NR | Overall N: 4246G1: 1993G2: 2253 | Overall N: 4246G1: 1993G2: 2253 | Overall N: 4246G1: 1993G2: 2253 | RCT: cluster-randomized |
| Powers et al., 201168 | Overall N: 278G1: NRG2: NR | Overall N: 89G1: 44G2: 45 | Overall N: 89G1: 44G2: 45 | Overall N: 89G1: 44G2: 45 | RCT: parallel, not clustered |
| Pyne et al., 201141HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | Overall N: 448G1: NAG2: NA | Overall N: 276G1: 138G2: 138 | Overall N: 225G1: 105G2: 110 | Overall N: 249G1: 123G2: 126 | RCT: parallel, not clustered |
| Rich et al., 199642NA | Overall N: NRG1: NRG2: NR | Overall N: 156G1:80 G2: 76 | Overall N: NRG1: NRG2: NR | Overall N: 156G1:80 G2: 76 | RCT: parallel, not clustered |
| Rickles et al., 200543NA | Overall N: 63G1: G2:  | Overall N: 63G1: 31G2: 32 | Overall N: G1: 28G2:32 | Overall N:G1: 28G2: 32 | RCT: parallel, not clustered |
| Ross et al., 200444NR | Overall N: NRG1: NRG2: NR | Overall N: 107G1: 54G2: 53 | Overall N: 81 G1: 38G2: 43 | Overall N: NRG1: NRG2: NR | RCT: parallel, not clustered |
| Rudd et al., 200445NA | Overall N: 837G1: NRG2: NR | Overall N: 150G1: 74G2: 76 | Overall N: 137G1: 69G2: 68 | Overall N: 150G1: 74G2: 76 | RCT: parallel, not clustered |
| Rudd et al., 200946NA | Overall N: 408G1: G2:  | Overall N: 127G1: 64 (51 Individualized Care, 13 Plain English)G2: 63 | Overall N: 105G1: 48G2: 57 | Overall N: 127G1: 64G2: 63 | Other  |
| Schaffer et al., 200447NA | Overall N: NRG1: NRG2: NRG3: NRG4:NR | Overall N: 46G1: NRG2: NRG3: NRG4:NR | Overall N: 44G1: NRG2: NR | Overall N: 46 G1: 11G2: 10G3:12G4:13 | RCT: parallel, not clustered |
| Schectman et al., 199448NA | Overall N: NRNiacinG1: 102BASG2: 62 | NiacinOverall N: 102G1: 52G2: 50BASOverall N: 62G1: 31G2: 31 | NiacinOverall N: 102G1: 52G2: 50BASOverall N: 60G1: 29G2: 31 | NiacinOverall N: 80G1: 40G2: 40BASOverall N: 40G1: 18G2: 22 | RCT: parallel, not clustered |
| Schneider et al., 200849NA | Overall N: 112G1: NRG2: NR | Overall N: 93G1: NRG2: NR | Overall N: 85G1: 47G2: 38 | Overall N: 85G1: 47G2: 38 | RCT: parallel, not clustered |
| Schnipper et al., 200650NA | Overall N: 291G1: G2:  | Overall N: 178G1: 92G2: 84 | Overall N: 152G1: 79G2: 73 | Overall N: 152G1: 79G2: 73 | RCT: parallel, not clustered |
| Simon et al., 200651NA | Overall N: 217G1: NRG2: NR | Overall N: 207G1: NRG2: NR | Overall N: NRG1: NRG2: NR | Overall N: G1: symptom analysis:94utilization analysis: 98G2: symptom analysis: 94utilization analysis: 97 | RCT: parallel, not clustered |
| Sledge et al., 200652NA | Overall N: 238G1: G2:  | Overall N: 96G1: 47G2: 49 | Overall N: 75G1: 36G2: 39 | Overall N: 75G1: 36G2: 39 | RCT: parallel, not clustered |
| Smith et al., 200853NR | Overall N: NRG1: NRG2: NR | Overall N: 907G1: 458G2: 449 | Overall N: 836G1: 426G2: 410 | Overall N: 836G1: 426G2: 410 | RCT: cluster-randomized |
| Solomon et al., 199854NAGourley et al., 199855NA | Overall N: NRG1: NRG2: NR | Overall N: NRG1: NRG2: NR | Overall N: HTN:133 COPD:98G1 (HTN): 63G2 (HTN): 70G1 (COPD): 43G2 (COPD): 55 | Overall N: HTN: 133COPD: 98G1 (HTN): 63G2 (HTN):70G1 (COPD): 43G2 (COPD): 55 | RCT: parallel, not clustered |
| Stacy et al., 200956NA | Overall N: 5174G1: G2:  | Overall N: 578G1: 298G2: 280 | Overall N: 497G1: 253G2: 244 | Overall N: 497G1: 253G2: 244 | RCT: parallel, not clustered |
| Taylor et al., 200357NA | Overall N: NRG1: G2:  | Overall N: 81G1: NRG2: NR | Overall N: 69G1: 33G2: 36 | Overall N: 69G1: 33G2: 36 | RCT: parallel, not clustered |
| Vivian et al., 200258NA | Overall N: 56G1: NAG2: NA | Overall N: 56 G1: 27G2: 29 | Overall N: 53G1: 26G2: 27 | Overall N: 53G1: 26G2: 27 | RCT: parallel, not clustered |
| Waalen et al., 200959NA | Overall N: 442G1: G2:  | Overall N: 235G1: 125G2: 110 | Overall N: 211G1: 109G2: 102 | Overall N: 211G1: 109G2: 102 | RCT: parallel, not clustered |
| Wakefield et al., 201160 | Overall N: 304G1: NRG2: NRG3:NR | Overall N: 302G1: 93G2: 102G3: 107 | Overall N: 246G1: 73G2: 79G3: 94 | Overall N: NRG1: NRG2: NRG3:NR | RCT: parallel, not clustered |
| Weinberger et al., 200261NA | Overall N: 14195G1: NRG2: NRG3:NReligible for initial criteria | Overall N: 1113 G1: 446G2: 363G3: 303 | Overall N: 898G1: 356G2: 296G3: 246 | Overall N: 898G1: 356G2: 296G3: 246 | RCT: cluster-randomized |
| Weymiller et al., 200762Statin Choice Randomized TrialJones et al., 200963Statin Choice Randomized Trial | Overall N: 124G1: NAG2: NA | Overall N: 98G1: 52G2: 46 | Overall N: 97G1: 51G2: 46 | Overall N: 97G1: 51G2: 46 | RCT: cluster-randomized |
| Williams et al., 201064NA | Overall N: 207 MDs (34 practices)G1: NAG2: NA | Overall N: 34 practices (207 providers);G1: 17 practices (88 providers; 1335 patients)G2: 17 practices (105 providers; 1363 patients) | Overall N: 34 practices (206 providers)G1: 17 practices (87 providers; 1040 patients); G2: 17 practices (105 providers; 1034 patients) | Overall N: G1: G2:  | RCT: cluster-randomized |
| Wilson et al., 201065Better Outcomes of Asthma Treatment (BOAT)  | Overall N: 1070G1: G2:  | Overall N: 612G1: 204G2: 204G3: 204 | Overall N: 551G1: 182G2: 180G3: 189 | Varies by outcome | RCT: parallel, not clustered |
| Wolever et al., 201066NA | Overall N: 64G1: NRG2: NR | Overall N: 56G1: 30G2: 26 | Overall N: 47G1: 25G2: 22 | Overall N: 49G1: 27G2: 22 | RCT: parallel, not clustered |
| Zhang et al., 201067NA | Overall N: 20,889G1,G2,G3: Total of 14,965G4: 5,924 | NA | NA | Overall N: 20,889G1, G2, G3: Total of 14,965G4: 5924 | Before-after study |